Healthy Adult Subjects
Conditions
Brief summary
To assess the bioequivalence of esomeprazole of the TEST product vs. the REFERENCE product in healthy volunteers who reside in Taiwan.
Detailed description
This study is designed to assess the bioequivalence of esomeprazole of the TEST product vs. the REFERENCE product in healthy volunteers who reside in Taiwan. Bioequivalence will be assumed if the 90% confidence interval of the AUC0-t, AUC0-inf and Cmax ratio are within the 80-125% interval for log-transformed values.
Interventions
DRUGNexium powder for injection and infusion 40 mg
Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
DRUGEsomelone Powder for Solution for Injection / Infusion 40 mg
Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Sponsors
Yung Shin Pharmaceutical Ind. Co., Ltd.
isRed Pharma & Biotech Research Corporation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult, aged between 20 to 40 years old. 2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests, chest x-ray and electrocardiogram. 3. The normal range of the body mass index should between 18.5 and 25. 4. Normal laboratory determinations results including: SGOT (AST), SGPT (ALT), albumin, glucose, creatinine, uric acid, cholesterol, TG, γ-GT, alkaline phosphatase, total bilirubin, BUN, HBsAg, Anti-HCV and Anti-HIV test. 5. Normal hematology results including: hemoglobin, hematocrit, WBC count with differential, RBC count and platelet count. 6. Normal urinalysis results including: glucose, protein, RBC, WBC, epith, casts and bacteria. 7. Female subject who is: * using adequate contraception since last menstruation and no plan for conception during the study. * non-lactating. * has negative pregnancy test (urine) within 14 days prior to the study. 8. Informed consent form signed.
Exclusion criteria
1. A history of drug or alcohol abuse during the past 24 weeks. 2. Sensitivity to analogous drug. 3. A clinically significant illness (such as significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, melaena or gastric ulcer) within the past 4 weeks. 4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoetic, neurological, pulmonary or gastrointestinal pathology within the past 4 weeks. 5. Planed vaccination during the time course of the study. 6. Participation of any clinical investigation during the last 60 days. 7. Regular use of any medication during the last 4 weeks. 8. Single use of any medication during the last 2 weeks. 9. Blood donation of more than 250 mL within the past 12 weeks. 10. Individuals are judged by the investigator or co-investigator to be undesirable as subjects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bioequivalence will be assumed if the 90% confidence interval of the AUC0-t, AUC0-inf and Cmax ratio are within the 80-125% interval for log-transformed values. | Sampling Schedule: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 12 hr | The calculation of the respective pharmacokinetic will be based upon the reported concentrations and sampling times. |
Countries
Taiwan
Contacts
Primary ContactChen Chi Yuan
Outcome results
None listed